Company intelligence / Profile preview

IntegerBio

Gaithersburg, Maryland, United Statesinteger.bio ↗
Ownership
Private
Development stage
Preclinical
01

Overview

IntegerBio has demonstrated therapeutic effects in animal models of disease using nanobody technology licensed from the Franklin Institute. The company is currently working on two simultaneous programs focusing on different coronavirus subunits.

Therapeutic areas
Infectious Diseases
Modalities
Nanobody technologyImmunovirology therapeutics
Industry
Biotech
02

Drug pipeline

2 assets

SYNFERON

Preclinical

1 more asset in the full pipeline.

03

Partnerships

The Franklin (Rosalind Franklin Institute)

Beyond the preview

Go deeper on IntegerBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntegerBio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call